ArticleFrontiers in oncology2023

Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.

Lijun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.